Foreground: Dr. Vidadi Yusibov, Executive
Director, Fraunhofer CMB explains the process of producing
vaccines in plants.
Left to right behind Dr. Yusibov:
1. Fred Sears, Executive Director, Delaware Community
Foundation
2. David McBride, Delaware State Senator
3. Mr. Cameron Yorkston, Yorkston Consulting
4. Terry Spence, Delaware State Representative
5. Mrs. Kathy Yorkston
6. Robert Venables, Delaware State Senator
|
|
Fraunhofer
Center for Molecular Biotechnology (CMB)
We have new technology for safer vaccine development that will
soon lead the way to protection for the entire U.S. population
from bioterrorism threats. Public health benefits will accrue,
as well. This new technology is cheaper, safer and takes much
less production time than current practices. It's a particular
type of plant science known as Transient Gene Expression (TGE).
|
|
Our core platform
technologies are employed in the following business areas to
help partners effectively and efficiently meet their protein
production needs:
Vaccines
Transient gene expression provide a particularly effective
modality for developing vaccines used in the prevention and
treatment of diseases, including applications for anti-bioterrorism.
Protein
Therapeutics
Molecular farming offers a safer and less expensive means of
producing monoclonal antibodies (Mabs) while eliminating the
risk of contamination by animal pathogens, with low investment
scale-up.
Industrial
Enzymes
Molecular farming stimulates higher yield and significantly
reduces the costs associated with industrial biocatalysis;
while directed evolution allows improvement of enzyme
function.
Ag Biotech
Transient gene expression helps define the function of new
genes and can be used to alter the metabolism of plants for
the production of desired metabolites.
|
